

CORRECTED VERSION

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
19 May 2005 (19.05.2005)

PCT

(10) International Publication Number
WO 2005/045038 A2

(51) International Patent Classification⁷: C12N 15/11

(21) International Application Number:
PCT/US2004/027231

(22) International Filing Date: 20 August 2004 (20.08.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

10/693,059	23 October 2003 (23.10.2003)	US
10/720,448	24 November 2003 (24.11.2003)	US
10/727,780	3 December 2003 (03.12.2003)	US
10/757,803	14 January 2004 (14.01.2004)	US
60/543,480	10 February 2004 (10.02.2004)	US
10/780,447	13 February 2004 (13.02.2004)	US
10/826,966	16 April 2004 (16.04.2004)	US
PCT/US04/13456	30 April 2004 (30.04.2004)	US
60/570,086	11 May 2004 (11.05.2004)	US
PCT/US04/16390	24 May 2004 (24.05.2004)	US

(71) Applicant (for all designated States except US): SIRNA
THERAPEUTICS, INC. [US/US]; 2950 Wilderness
Place, Boulder, CO 80301 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): RICHARDS, Ivan
[US/US]; 3533 East D. Avenue, Kalamazoo, MI 49009
(US). POLISKY, Barry [US/US]; 449 Mountain View
Road, Boulder, CO 80302 (US). MCSWIGGEN, James
[US/US]; 4866 Franklin Drive, Boulder, CO 80301 (US).

(74) Agent: TERPSTRA, Anita, J.; McDonnell Boehnen Hul-
bert & Berghoff LLP, 300 South Wacker Drive, Suite 3100,
Chicago, IL 60606 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished
upon receipt of that report

(48) Date of publication of this corrected version:
14 July 2005

(15) Information about Correction:

see PCT Gazette No. 28/2005 of 14 July 2005, Section II

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: RNA INTERFERENCE MEDIATED INHIBITION OF GPRA AND AAA1 GENE EXPRESSION USING SHORT
NUCLEIC ACID (siNA)

(57) Abstract: This invention relates to compounds, compositions, and methods useful for modulating G protein-coupled receptor
for asthma susceptibility (GPRA) and asthma-associated alternatively spliced gene 1 (AAA1) gene expression using short interfer-
ing nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the
expression and activity of other genes involved in pathways of GPRA and/or AAA1 gene expression and/or activity by RNA inter-
ference (RNAi) using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such
as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and
short hairpin RNA (shRNA) molecules and methods used to modulate the expression of GPRA and/or AAA1 genes.